http://orcid.org/0000-0002-6678-2629
References
- Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010;39:707–12.
- Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004;240:117–22.
- Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–59.
- Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123–31.
- Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813–29.
- Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999;340:858–68.
- Pavel M, Grossman A, Arnold R, et al. ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology 2010;91:326–32.
- Kang H, O'Connell JB, Leonardi MJ, et al. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis 2007;22:183–9.
- Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases. J Exp Clin Cancer Res 2000;19:271–80.
- Eichhorn JH, Young RH. Neuroendocrine tumors of the genital tract. Am J Clin Pathol 2001;115:94–112.
- Talerman A. Carcinoid tumors of the ovary. J Cancer Res Clin Oncol 1984;107:125–35.
- Feldman JM. Carcinoid tumors and syndrome. Semin Oncol 1987;14:237–46.
- Maton PN. The carcinoid syndrome. Jama 1988;260:1602–5.
- Pellikka PA, Tajik AJ, Khandheria BK, et al. Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 1993;87:1188–97.
- Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastroenteropancreatic tumours. Neuroendocrinology 2004;80:35–8.
- Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology 2009;90:167–83.
- Nikou GC, Lygidakis NJ, Toubanakis C, et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 2005;52:731–41.
- O’Toole D, Grossman A, Gross D, et al. ENETS consensus guidelines for standards of care in neuroendocrine tumors: biochemical markers. Neuroendocrinology 2009;90:194–202.
- Korse CM, Taal BG, de Groot CA, et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009;27:4293–9.
- van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl 2006;12:448–56.
- Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241:776–83.
- Norton JA, Kivlen M, Li M, et al. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859–66.
- Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.